Incidence of colon and rectal cancers are increasing sharply in people younger than 50 years, the recommended age for initiating screening.
Outcomes improved with short-course radiation and delay to surgery of 4 to 8 weeks.
In this study, the impact of advancements in surgical technique and systemic therapy for stage II and III rectal cancers was assessed via a comparison of outcomes after neoadjuvant chemoradiotherapy followed by definitive resection with those for neoadjuvant multiagent chemotherapy without radiation therapy.
Poor compliance to NCCN guidelines for adjuvant chemotherapy appears to be associated with poorer overall survival.
Use of neoadjuvant chemoradiotherapy (NACRT) before surgery among patients with rectal cancer has substantially increased over the past decade.
Nearly 50% of patients with stage II/III rectal cancer achieve a complete clinical response via neoadjuvant chemoradiation.
A new study indicates that patient travel distance to an appropriate treatment facility can impact whether radiation therapy is received.
Patients with rectal cancer reported aerobic exercise during neoadjuvant chemoradiotherapy to be more enjoyable and less difficult.
No difference in local efficacy was found between two treatment regimens for colorectal cancer: short-course (5-day) radiation followed by consolidation chemotherapy before surgery and standard 5-week chemoradiation.
Patients who had the procedure eight weeks after chemo and radiation therapy demonstrated the best survival rates.
Baseline dietary glutamic acid intake is associated with a lower risk for developing colorectal cancer, particularly in people who are not overweight.
Compared with open surgery, laparascopic surgery fails to improve outcomes for patients with stage 2 or 3 rectal cancer.
New study data associates the resection of colorectal cancer (CRC) liver metastases with greater risk of postoperative mortality among elderly patients.
Patients with colorectal cancer that is detected during a colonoscopy screening are more likely to survive to longer than patients who are not diagnosed until they have symptoms.
mFOLFOX6 administered concurrently with radiation therapy resulted in a higher pathological complete response in rectal cancer.
Patients with rectal cancer that experienced a complete response had similar 4-year survival rates regardless of whether they had immediate surgery or pursued a watch-and-wait approach.
A review of top clinical guidelines for rectal cancer shows a variety of treatment recommendations.
A new phase II study finds that if chemotherapy is offered before radiation and surgery, more patients will be able to tolerate it and receive a full regimen of treatment.
Long-term results of an EORTC trial show that 5- fluorouracil (FU)-based adjuvant chemotherapy after preoperative chemoradiotherapy for patients with cT3-resectable T4 M0 rectal cancer does not improve survival or disease-free survival.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Early end-of-life talks are associated with less aggressive care and greater use of hospice services when patients do reach their final days.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Two of three main recommendations for colonoscopy surveillance are now supported by stronger evidence than they were in 2006.
I knew Sam's joking was not a sign of joy or happiness but his way of coping, maybe the only way he knew how.
No significant differences in rates of local, distant recurrence; overall survival; or late toxicity.
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
CT colonography can accurately detect adenomas 10 mm or larger in patients who did not undergo laxative-induced bowel cleansing before the procedure.
Childhood cancer survivors may need earlier colorectal cancer screening, especially if abdominal radiation was part of their treatment.
CT colonography accurately detects cancer and precancerous polyps in persons aged 65 years and older.
Dabrafenib, which targets a genetic mutation that is active in half of melanoma cases, substantially and safely shrank metastatic tumors.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|